Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Equillium, Inc.

< Previous 1 2 Next >
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Host Analyst & Investor Day
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at the JonesTrading 2023 Healthcare Summit
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces $7.5 Million Share Repurchase Program
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Tickers EQ
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
From Equillium, Inc.
Via Business Wire
Tickers EQ
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.